ArticleThe EPMA journal2022

TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine.

Simeng Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.